Aligos Therapeutics

NASDAQ: ALGS ↗$6.67 USDSmall-cap (clinical stage, ~$100M range as of August 2026) MCAP

#Chronic Hepatitis B (HBV)#Metabolic Dysfunction-Associated Steatohepatitis (MASH)#Obesity #Coronavirus / Viral Disease

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for liver and viral diseases, with a lead focus on chronic hepatitis B. Its pipeline includes pevifoscorvir sodium, a capsid assembly modulator in Phase 2b for chronic HBV; ALG-055009, a THR-beta agonist in Phase 2a for metabolic dysfunction-associated steatohepatitis (MASH) and obesity; and ALG-097558, a ritonavir-free pan-coronavirus protease inhibitor that has completed Phase 1. In Q2 2026 the company reported $27.8 million in revenue, driven by a $25 million China licensing deal, and narrowed its net loss to $1.5 million.

Company Info

Sector:Clinical-Stage Biotechnology / Antivirals & Liver Disease

Headquarters:South San Francisco, California, USA

Founded:2018

Website:www.aligos.com/

Upcoming Milestones & Key Dates

Q3 2026

Clinical

Continued Phase 2b enrollment for pevifoscorvir sodium in chronic HBV

Clinical Development Pipeline

Pevifoscorvir sodium (ALG-000184)

Target: Capsid assembly modulator

Chronic Hepatitis B

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ALG-055009

Target: THR-beta agonist

MASH and obesity

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ALG-097558

Target: Ritonavir-free pan-coronavirus protease inhibitor

Coronavirus infection

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Lawrence M. Blatt, Ph.D., M.B.A.

Chief Executive Officer, President and Chairman

Lesley Ann Calhoun, CPA

Executive Vice President, Chief Financial Officer and Chief Operating Officer

Careers & Job Openings

No active job listings. Check back later.